Shankar Ram, Schmeer Marco, Schleef Martin
PlasmidFactory GmbH, Bielefeld, Germany.
Methods Mol Biol. 2024;2786:303-319. doi: 10.1007/978-1-0716-3770-8_14.
A plasmid production process has been established to manufacture plasmid DNA at a large scale in High-Quality grade. This is used as a starting material to produce mRNA vaccines for clinical trials. Recently, the World Health Organization (WHO) has released regulatory guidelines related to the quality, safety, and efficacy for DNA- as well as for mRNA-based vaccines. Following an extraordinary year of scientific, regulatory, and manufacturing developments, the scientific community today stands considerably better equipped to deal with urgent production requirements in large scale for nucleic acid-based vaccinations and therapies. Going forward, work needs to be done in better coordinating the supply and logistics of essential raw materials for biological manufacturing, especially under emergency conditions.
已建立了一种质粒生产工艺,用于大规模生产高质量等级的质粒DNA。这被用作生产用于临床试验的mRNA疫苗的起始材料。最近,世界卫生组织(WHO)发布了与DNA以及基于mRNA的疫苗的质量、安全性和有效性相关的监管指南。在经历了科学、监管和生产发展的非凡一年之后,科学界如今在应对基于核酸的疫苗接种和治疗的大规模紧急生产需求方面有了更好的准备。展望未来,需要开展工作,以更好地协调生物制造关键原材料的供应和物流,特别是在紧急情况下。